Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing

Journal of Crohn's and Colitis

Volumn 8, Issue 5, 2014, Pages 357-362

  Connolly, Mark P ^a,b   Kuyvenhoven, Johan P ^c   Postma, Maarten J ^a   Nielsen, Sandy K ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Global Market Access Solutions   (United States)

^c Department of Gastroenterology Kennemer Gasthuis ^*  (Netherlands)

^d Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Active disease; Mesalazine; Once daily; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; CORTICOSTEROID; ENEMA; INFLIXIMAB; MESALAZINE; PREDNISOLONE; GASTROINTESTINAL AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; HEALTH STATUS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; METHODOLOGY; NETHERLANDS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; NETHERLANDS; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 84897082547     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.09.015     Document Type: Article

References (25)

1. Baicker K., Chandra A., Skinner J. Saving money or just saving lives? Improving the productivity of US health care spending. Annu Rev Econ 2012, 4:33-56.
2. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
3. Sokol M., McGuigan K., Verbrugge R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
4. Buchanan J., Wordsworth S., Ahmad T., Perrin A., Vermeire S., Sans M., et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011, 5:301-316.
5. Connolly M.P., Nielsen S.K., Currie C.J., Poole C.D., Travis S.P. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis 2009, 3:32-37.
6. Kane S., Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008, 53:1020-1024.
7. Dignass A., Eliakim R., Magro F., Maaser C., Chowers Y., Geboes K., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: definitions and diagnosis. J Crohns Colitis 2012, 6:965-990.
8. Kane S.V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577-585.
9. Flourié B., Hagège H., Tucat G., Maetz D., Hébuterne X., Kuyvenhoven J.P., et al. Aoucheta D; MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013, 37:767-775.
10. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut 2005, 54:960-965.
11. Centraal Begeleidings Orgaan (CBO) Richtlijn diagnostiek en behandeling van inflammatoire darmziekten bij volwassenen [Accessed March 4, 2012, at]. http://www.icc-ibd.com/richtlijn.
12. Connolly M.P., Nielsen S.K., Currie C.J., Marteau P., Probert C.S., Travis S.P. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis 2009, 3:168-174.
13. College voor zorgverzekeringen (CVZ) A background study on the 'cost effectiveness' package principle for the benefit of the appraisal phase in package management [Accessed March 5, 2012 at]. http://www.cvz.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2010/1011-a-background-study-on-the-%E2%80%98costeffectiveness%E2%80%99-package-principle-for-the-benefit-of-the-appraisal-phase-in-package-management/A+background+study+on+the+%E2%80%98costeffectiveness%E2%80%99+package+principle+for+the+benefit+of+the+appraisal+phase+in+package+management.pdf.
14. Poole C.D., Connolly M.P., Nielsen S.K., Currie C.J., Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis 2010, 4:275-282.
15. Nederlandse Zorgautoriteit (NZA) Tarieventabel DBC-zorgproducten en overige producten - per 1 september 2012 Accessed September 30, 2012 at. http://www.nza.nl/regelgeving/tarieven/ziekenhuiszorg/tarievenDBCDOT/tarieven-prestaties-DBC-DOT/.
16. Z-Index Official Dutch Drug Prices: G-standard of Z-index: The Hague 2010 [Accessed September 30, 2012 at]. http://www.z-index.nl/.
17. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005, 8:1-2.
18. Baron J.H., Connell A.M., Kanaghinis T.G., Lennard-Jones J.E., Avery Jones F. An assessment of prednisone, salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960, 1:217-222.
19. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
20. Burisch J., Jess T., Martinato M., Lakatos P.L. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013, 7:322-337.
21. Ghosh S., Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007, 1:10-20.
22. Rogala L., Miller N., Graff L.A., Rawsthorne P., Clara I., Walker J.R., et al. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:526-535.
23. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. Colombel JF; European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
24. Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003, 18:191-198.
25. Kruis W., Kiudelis G., Racz I., Gorelov I.A., Pokrotnieks J., Horynski M., et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009, 58:233-240.